Entecavir: a step forward in combating hepatitis B disease
Authors:
- 12 November 2008
- journal article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 9 (17) , 3095-3109
Abstract
(2008). Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy: Vol. 9, No. 17, pp. 3095-3109. doi: 10.1517/14656560802515546Keywords
This publication has 62 references indexed in Scilit:
- Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma InhibitionAntimicrobial Agents and Chemotherapy, 2008
- Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patientsJournal of Hepatology, 2007
- Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in ChinaHepatology International, 2007
- The HBV Drug Entecavir — Effects on HIV-1 Replication and ResistanceNew England Journal of Medicine, 2007
- Inhibition of Hepatitis B Virus Polymerase by EntecavirJournal of Virology, 2007
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Viral dynamics during and after entecavir therapy in patients with chronic hepatitis BJournal of Hepatology, 2002